Noninvasive imaging strategies will be critical for defining the temporal characteristics of angiogenesis and assessing efficacy of angiogenic therapies. The αvβ3 integrin is expressed in angiogenic vessels and represents a potential novel target for imaging myocardial angiogenesis. We demonstrated the localization of an indium-111-labeled ( 111 In-labeled) αvβ3-targeted agent in the region of injury-induced angiogenesis in a chronic rat model of infarction. The specificity of the targeted αvβ3-imaging agent for angiogenesis was established using a nonspecific control agent. The potential of this radiolabeled αvβ3-targeted agent for in vivo imaging was then confirmed in a canine model of postinfarction angiogenesis. Serial in vivo dual-isotope single-photon emission-computed tomographic (SPECT) imaging with the 111 In-labeled αvβ3-targeted agent demonstrated focal radiotracer uptake in hypoperfused regions where angiogenesis was stimulated. There was a fourfold increase in myocardial radiotracer uptake in the infarct region associated with histological evidence of angiogenesis and increased expression of the αvβ3 integrin. Thus, angiogenesis in the heart can be imaged noninvasively with an 111 In-labeled αvβ3-targeted agent. The noninvasive evaluation of angiogenesis may have important implications for risk stratification of patients following myocardial infarction. This approach may also have significant clinical utility for noninvasively tracking therapeutic myocardial angiogenesis.
Introduction
Angiogenesis represents the formation of new capillaries by cellular outgrowth from existing microvessels (1) and occurs as part of the natural healing process following ischemic injury. Angiogenesis is associated with postinfarct remodeling and has important implications for prognosis following myocardial infarction. Therefore, the noninvasive evaluation of angiogenesis may help predict left ventricular remodeling and permit risk stratification of patients following myocardial infarction. In addition, newer therapies for treatment of ischemic heart disease involve stimulation of this natural response. Many approaches to therapeutic myocardial angiogenesis have been explored, including gene therapy, intramyocardial administration of angiogenic factors, and transmyocardial revascularization (2) (3) (4) (5) (6) (7) (8) (9) (10) . While treatment with factors such as VEGF and bFGF has produced encouraging results in animal models (2) (3) (4) and in early clinical trials (7, 11) , double-blind, placebo-controlled clinical studies to date have resulted in less-favorable outcomes (8, 10) . These seemingly contradictory findings may be directly related to the limitations of existing clinical methods directed at noninvasive evaluation of the physiological effects of angiogenesis, which may be very focal or nontransmural and therefore difficult to detect noninvasively. Unfortunately, standard cardiac noninvasive imaging strategies have not been effective in evaluation of cardiac angiogenesis (12) . The development of more sensitive and specific imaging strategies for the direct evaluation of myocardial angiogenesis, and tracking this process noninvasively, will be critical in evaluation of patients following myocardial infarction and in assessing new angiogenic therapy for the heart.
The angiogenic response is modulated by the composition of the ECM and intercellular adhesions, including integrins (13, 14) . Integrins are a family of heterodimeric cell surface receptors capable of mediating an array of cellular processes, including cell adhesion, migration, proliferation, differentiation, and survival (15) . During angiogenesis endothelial cells must adhere to one another and to the ECM in order to construct and extend new microvessels. The specific αvβ3 integrin has been identified as a critical modulator of angiogenesis (14) .
Angiogenic vessels demonstrate increased expression of the αvβ3 integrin; therefore the αvβ3 integrin represents a potential novel target for directly imaging angiogenesis (16, 17) . Investigators have proposed the potential noninvasive detection of tumor angiogenesis in vivo using magnetic resonance imaging and a paramagnetic contrast agent targeted to endothelial αvβ3 via the mAb for the αvβ3 integrin (LM609) (16) . Haubner et al. reported the synthesis and favorable imaging characteristics of a iodine-125-labeled ( 125 I-labeled) αvβ3 antagonist (17) (18) (19) . Harris et al. recently reported the high affinity and selectivity of an indium-111-labeled quinolone ( 111 In-RP748) for the αvβ3 integrin using assays of integrin-mediated adhesion (20) . These investigators also demonstrated a rapid blood clearance and favorable biodistribution of 111 In-RP748 and the feasibility for tumor imaging. We recently demonstrated that 111 In-RP748 binds preferentially to activated αvβ3 on endothelial cells in vitro and exhibits favorable binding characteristics for in vivo imaging (21) . These preliminary in vitro studies and work in imaging tumor angiogenesis supports the potential for radiolabeled targeting of αvβ3 for imaging of myocardial angiogenesis.
We hypothesized that the angiogenic process in the heart can be directly tracked noninvasively by single-photon emission-computed tomographic (SPECT) imaging of radiolabeled ligands targeted at the αvβ3 integrin. The purpose of the current study was to evaluate 111 In-RP748, a radiolabeled quinolone targeted at αvβ3, for imaging of ischemia-induced angiogenesis following ischemic injury in established rodent and canine models of myocardial infarction. The chemical structure of 111 In-RP748 is shown in Figure 1A . We evaluate the uptake of 111 In-RP748 following ischemic injury, in relation to immunohistochemical markers of the angiogenic process and myocardial perfusion. The specificity of myocardial 111 In-RP748 uptake was demonstrated in a chronic rodent model of injury-induced myocardial angiogenesis using paired control experiments with an analogue compound ( Figure 1B) , which demonstrated no in vitro specificity for the αvβ3 integrin. Subsequent studies employing a chronic canine model of injury-induced myocardial angiogenesis demonstrated the feasibility of SPECT imaging for noninvasive detection of the αvβ3 integrin.
Methods
All experimental studies were performed with approval of the Institutional Animal Care and Use Committee, according to the guiding principles of the American Physiological Society on research animal use.
Rodent experiments
Rodent surgical preparation. A chronic rat model of infarction was employed using procedures modified from those previously reported (22) . Male Sprague-Dawley rats (200-250 g) were anesthetized with isoflurane, and the hearts were exposed by a limited left anterolateral thoracotomy. A 6-0 proline ligature was used to occlude the left anterior descending (LAD) coronary artery 7 mm distal to its origin. Serial brief preconditioning occlusions were performed to suppress ventricular dysrhythmias, followed by a 45-minute experimental occlusion. The coronary occlusion was then released, and the chest was closed in layers.
Rodent experimental protocol. Two weeks after myocardial infarction, rats (n = 11) were injected intravenously with either 111 In-RP748 (1.2 ± 0.1 mCi), an agent targeted at the αvβ3 integrin, or 111 In-RP790 (1.2 ± 0.1 mCi), a nonspecific control agent. Ninety minutes after injection of one of the 111 In-labeled agents, rats were injected with thallium-201 ( 201 Tl; 0.78 ± 0.06 mCi) for evaluation of relative myocardial perfusion. Rats were euthanized 30 minutes after 201 Tl injection for postmortem analysis of myocardial tissue activity. The myocardial uptake of the 111 In-labeled agents was compared to relative 201 Tl perfusion and immunohistochemical markers of the angiogenic process.
Postmortem analysis of rat hearts. Rodent hearts were excised and filled with dental molding material (alginate impression material, type II -normal set; Quala Dental Products, Milford, Delaware, USA) to facilitate cutting of the hearts into uniform 2-mm-thick slices. Selected slices were frozen and sectioned for immunohistochemistry of both lectin (marker of endothelium) αv and β3. Unstained heart slices were then cut into eight transmural segments for γ-well counting of 201 Tl and 111 In activity, using two energy windows ( 201 Tl: 60-90 keV; 111 In: 170-300 keV). Raw counts were corrected for spill-up/spill-down, background, decay, and weight. The corrected counts were normalized to a nonischemic region of the heart, and the segments were segregated by myocardial 201 Tl retention into one of four groups: 0-40%, 41-60%, 61-80%, or 80-120% nonischemic.
Canine experiments
Studies were also performed in dogs (n = 6) with injury-induced myocardial angiogenesis in order to better define the expression of the αvβ3 integrin in the region of myocardial injury, to better localize the uptake of 111 In-RP748 in relationship to myocardial injury and perfusion, and to establish the feasibility of in vivo imaging of myocardial angiogenesis with 111 In-RP748.
Canine surgical preparation. Six fasted adult mongrel dogs were injected with 10 mg/kg thiopental sodium intravenously and were intubated. Animals were placed on a respirator and mechanically ventilated with nitrous oxide and oxygen (3:1) and 0.5-1.5% halothane. Dogs underwent cardiac catheterization via the right femoral artery, using a standard coronary guide catheter, and a baseline angiogram was obtained. Either the proximal LAD or left circumflex coronary artery was occluded for 2 hours using a balloon angioplasty catheter (diameter: 2.5 mm; length: 20 mm) under fluoroscopic guidance. The balloon was inflated to a pressure of 4 atm. An angiogram was performed immediately after inflation and every 15 minutes thereafter to confirm coronary occlusion. The coronary occlusion was released after 2 hours, and coronary reflow was confirmed angiographically. An angiogram was performed prior to each nuclear-imaging session to confirm vessel patency.
Figure 1
Structure of 111 In-RP748, a quinolone targeted at αvβ3 integrin (A), and control compound (B). 111 In-labeled αvβ3 and perfusion. All dogs (n = 6) underwent dual isotope SPECT imaging with 111 In-RP748 and Technetium-99m-labeled ( 99m Tc-labeled) 2-methoxy-2-metholpropyl-isonitrile (sestamibi). Dogs were imaged following 6-10 hours of reperfusion, as well as at 1 and 3 weeks after reperfusion. Following intravenous injection of 111 In-RP748 (6.6 ± 1.0 mCi), six serial 15-minute SPECT images were acquired starting at 15 minutes after injection. The last SPECT acquisition was initiated 90 minutes after injection. Images were acquired using two energy windows, 180 keV ± 7.5% and 252 keV ± 10%, grouped into a single image. All nuclear imaging was done on a Dual-Head Gamma Camera (GE Millennium; General Electric Corp., Waukesha, Wisconsin, USA), using medium energy parallel-hole collimators. SPECT images were acquired in continuous advance mode, 15 seconds per 3° frame, with a zoom of 1.77 and 64 × 64 matrix. Following the 111 In-RP748 SPECT imaging, 22.3 ± 5.4 mCi of 99m Tc-sestamibi was injected. A 15-minute SPECT 99m Tc-sestamibi image was acquired 15 minutes after injection to provide a reference perfusion image facilitating reconstruction of the 111 In-RP748 "hot spot" image. Acquisition parameters were identical to those used for the 111 In-RP748 SPECT acquisitions, except for an energy window center at 140 keV (± 7.5%).
In vivo SPECT imaging of
All SPECT images were batch reconstructed using standard filtered back projection (order 4, cutoff 0.28 × Nyquest frequency) without attenuation or scatter correction. To quantify the relative signal-to-noise ratio in our reconstructed SPECT images, equal-size regions of interest were drawn over the targeted hot spot and remote myocardial regions. The remote myocardial region was localized within the myocardium on the targeted image based on a location defined by the registered perfusion images.
Postmortem analysis in canine model. Three weeks after reperfusion, following the last imaging session, dogs were euthanized and hearts rapidly excised. Transmural myocardial sections were cut from the normal and central infarct regions of the heart, and tissue from each biopsy was split into two transmural sections. One half was fixed in 10% formalin solution and later embedded in paraffin. The other half of each biopsy was frozen in embedding compound (Tissue-Tek OCT; Sakura Finetek USA Inc., Torrance, California, USA) using a bath of 2-methylbutane cooled on dry ice.
Ex vivo imaging of 111 In-labeled αvβ3 and perfusion. After left ventricle tissue was obtained from biopsies, the heart was cast with dental impression material and sliced into uniform short axis slices (5 mm). Cast slices were placed in direct contact with the medium energy collimator surface of the gamma camera in order to obtain registered sequential high-resolution (256 × 256) 99m Tc-sestamibi and 111 In-RP748 images using the previously defined energy windows.
Postmortem analysis of canine hearts. Heart slices were stained with a buffered solution of 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) at 38°C to identify myocardial infarction. Digital photographs were taken of both the apical and basal surfaces of all stained slices.
Heart slices were stripped of epicardial fat and surface vessels, cut into eight radial pies, and each pie was divided transmurally into epicardial and endocardial pieces for γ-well counting using two energy windows ( 99m Tc: 130-150 keV; 111 In: 170-300 keV). Raw γ counts were corrected for background, decay, spill-up/spill-down and were expressed as counts per minute per gram of tissue. Activity in each myocardial sample was normalized to the activity in a nonischemic region of the heart. Tissue activities were grouped according to normalized 99m Tc-sestamibi activity into one of four groups: 0-40%, 41-60%, 61-80%, or 81-120% nonischemic.
Histological and immunohistochemical analysis
Formalin-fixed myocardial sections were stained with Masson's trichrome using standard techniques to define the area of fibrosis. Cryostat sections (5 μm thick) were used for immunohistochemical staining. For our immunohistochemical analysis of rat myocardial angiogenesis, sections stained with a biotinylated endothelial-specific lectin Bandeiraea Simplicifolia Lectin I (Vector Laboratories, Burlingame, California, USA). Since no specific Ab is available for rat αvβ3 integrin, we performed separate staining for αv (rabbit anti-integrin αv subunit polyclonal Ab; Chemicon International, Temecula, California, USA) and β3 (mouse anti-rat integrin β3 mAb; BD Biosciences PharMingen, San Diego, California, USA) integrins. Sections were then incubated with respective biotinylated secondary Ab's. The signal was detected using HRP avidin (Elite ABC VectaStain Kit; Vector Laboratories). The peroxidase label was developed using 3-(2-aminoethyl)carbazole (Red AEC Kit; Vector Laboratories), and the sections were counterstained with hematoxylin. Analysis of angiogenesis in dogs was accomplished with the
Figure 2
Immunohistochemical analysis in chronic rat model. Example of lectin, αv, and β3 staining is shown for normal and infarct region (A) in rats 2 weeks following infarction. The infarct region demonstrated an increase in capillary density and arterioles, as well as increased staining for αv and β3. This was confirmed by quantitative analysis (B). *P < 0.05 vs. normal.
biotinylated endothelial-specific lectin, Bandeiraea Simplicifolia Lectin I (Vector Laboratories). For immunostaining of the αvβ3 integrin in dogs, we used a specific mouse mAb for the αvβ3 integrin (LM609; Chemicon International).
Sections were analyzed quantitatively for extent (percentage of area) of positive staining using computer algorithms developed and validated in our laboratory, which take into account the image hue, saturation, and intensity color map. Quantitative values for infarct and control regions in each animal were calculated by averaging results for four representative high-powered fields (×200) in each region.
Canine cell culture studies Canine femoral vein endothelial cells were isolated by scraping and were cultured as previously described (21) . A cy3-labeled homologue (TA145) of 111 In-RP748 was used to confirm and localize endothelial cell binding. The localization of TA145 was compared with that of LM609. LM609 is a mAb for the αvβ3 integrin, which has been previously demonstrated to bind to canine microvascular endothelial cells on frozen tissue sections from reperfused infarcted regions (23) . The localization of TA145 and LM609 was also compared with an isotype-matched control Ab of LM609 (MOPC21).
Statistical analysis
All data are presented as mean plus or minus SD. Comparisons between two groups were made using either a paired or unpaired Student's t test. Differences between groups were considered significant at P values less than 0.05 (two-tailed).
Results

Rodent chronic myocardial infarct experiments
Studies were performed in rats (n = 11) with injury-induced myocardial angiogenesis. Immunohistochemical staining with an endothelial-specific lectin confirmed angiogenesis in the infarct region. In the absence of a specific anti-rat αvβ3 Ab, αv and β3
Figure 3
γ-Well counting of myocardial radiotracer activity in relationship to 201 Tl uptake in the chronic rat model. Data are shown for rats injected with either 111 In-RP748 (RP748) or control compound. Decreased myocardial 201 Tl uptake was consistently observed in the anterolateral wall, as shown in representative myocardial count profiles (A). Cntrl, control; ant, anterior; sept, septal; post, posterior; lat, lateral. Uptake of 111 In-RP748 was highest in infarcted regions with reduced 201 Tl retention. In contrast, myocardial uptake of the control compound tracked 201 Tl perfusion. On average the relative myocardial retention of 111 In-RP748 in the postischemic and infarcted regions was nearly twice that in regions with normal 201 Tl perfusion; however, no selective retention of the nonspecific control compound was observed (B). *P < 0.05 vs. 81-120%; # P < 0.05 vs. control.
Figure 4
Immunohistochemical analysis in chronic canine model. Masson's trichrome staining demonstrated increased vascular density in the fibrotic central infarct region, which was confirmed by lectin staining. The infarct region demonstrated increased staining for αvβ3 using the LM609 Ab (A). LM609 staining localized to the endothelial cells of capillaries and endothelial cells, as well as smooth muscle cells of small arterioles within the infarct region. Very little LM609 staining was in seen in remote noninfarcted regions. These regional differences in staining were confirmed by quantitative analysis (B). *P < 0.05 vs. normal. staining in this same region were performed and demonstrated increased expression of these integrins (Figure 2A ). These changes were confirmed by semiautomated quantitative analysis of the immunohistochemical stains ( Figure 2B ). Following in vivo injection of 111 In-RP748 and the perfusion tracer thallium-201 ( 201 Tl), γ-well counting of myocardial segments allowed quantification of relative myocardial 111 In-RP748 retention in relationship to myocardial perfusion. The 111 In-RP748 was selectively retained in the infarcted regions with reduced 201 Tl perfusion ( Figure 3A) . A twofold increase in the retention of 111 In-RP748 was observed in most ischemic regions at 2 weeks after infarction ( Figure 3B ). In contrast, a nonspecific control compound demonstrated no preferential retention in the infarct region. The specific retention of 111 In-RP748 in myocardial regions with injury-induced angiogenesis suggests that 111 In-RP748 might be a candidate radiotracer for the noninvasive imaging of myocardial angiogenesis.
Canine chronic myocardial infarct experiments
Immunohistochemical staining of endothelium and αvβ3 integrin. Representative immunohistochemical stains are shown in Figure 4A . Lectin histochemical staining for endothelium confirmed angiogenesis in the central infarct region of the chronically infarcted dogs. Immunohistochemical staining with LM609, a specific Ab for the αvβ3 integrin, also confirmed increased expression of the receptor in capillaries and of both the endothelium and smooth musculature of arterioles within the infarct region. Increased capillary staining was primarily seen in the peri-infarct region, while arteriolar smooth muscle staining with LM609 was observed within the central infarct region. Quantitative analysis demonstrated a significant increase in vascular staining in the infarct region and increased activation of the αvβ3 integrin in angiogenic vessels ( Figure 4B ). The relative increase in LM609 staining in the ischemic region (ischemic/nonischemic ratio) observed in the dogs significantly correlated (r = 0.84, P ≤ 0.05) with the relative increase in myocardial uptake of 111 In-RP748 within these same ischemic regions.
Postmortem tissue analysis in canine model. γ-Well counting of canine myocardial segments allowed quantification of the observed increase in relative myocardial 111 In-RP748 retention in relationship to myocardial perfusion. Myocardial segments with decreased perfusion, as determined by 99m Tc-sestamibi retention, demonstrate increased retention of 111 In-RP748. Figure 5 illustrates the circumferential changes in endocardial and epicardial 111 In-RP748 activity in relationship to 99m Tc-sestamibi activity and corresponding ex vivo images in one of the dogs euthanized 3 weeks following infarction. Tissue γ-well counting data are summarized in Figure  5B . Dogs with chronic infarction demonstrated almost a fourfold increase in relative myocardial 111 In-RP748 activity in the most ischemic regions as defined by 99m Tc-sestamibi.
Dual-isotope in vivo SPECT imaging of 111 In-RP748 and 99m
Tc-sestamibi perfusion. The heart rate and aortic pressure remained stable in all chronically infarcted dogs that underwent serial dual-isotope in vivo SPECT imaging. The average hemodynamic values for these dogs are summarized in Table 1 . Analysis of the in vivo 111 In-RP748 SPECT images required registration and batch reconstruction of 111 In-RP748 image data with 99m Tc-sestamibi perfusion images. All dogs demonstrated focal myocardial retention of 111 In-RP748 on in vivo SPECT imaging by 60 minutes after injection, at a time when blood pool activity had cleared. The increase in myocardial 111 In-RP748 activity correlated with a 99m Tc-sestamibi perfusion defect. The 111 In-RP748 image quality was generally excellent, with a favorable heart-tobackground activity ratio. The targeted (hot spot) myocardial activity-to-remote background activity ratio varied from 1:1 to 1.6:1. A representative series of 111 In-RP748 and corresponding 99m Tc-sestamibi SPECT images from a chronically infarcted dog is shown in Figure 6 . Serial dual-isotope 111 In-RP748 and 99m Tc-sestamibi SPECT imaging demonstrated retention of 111 In-RP748 in the infarct region (see Figure 6A) . A representative dual-isotope 111 In-RP748 and 99m Tc-sestamibi SPECT image series is shown in Figure 6B . Based on our analysis of the serial images, the maximum increase in myocardial 111 In-RP748 retention appeared to occur at 1 week after infarction.
Figure 5
Well counting of myocardial radiotracer activity in relationship to 99m Tc-sestamibi perfusion in chronic canine infarct model. Ex vivo 99m Tc-sestamibi perfusion (left) and 111 In-RP748 (right) images of representative myocardial slices from an infarcted dog, 3 wks after reperfusion, with the corresponding TTC-stained section (middle) (A). Corresponding circumferential 99m Tc-sestamibi (MIBI) and 111 In-RP748 count profiles are shown for both endocardial (ENDO) and epicardial (EPI) segments. Focal uptake of 111 In-RP748 is seen in infarct region on ex vivo images, and is confirmed by γ-well counting. Myocardial segments from all dogs were segregated into four categories based on relative 99m Tc-sestamibi perfusion (percentage nonischemic). Regional myocardial 111 In-RP748 activity (percentage nonischemic) was significantly increased 3 wks after reperfusion in the ischemic regions of all dogs (B). # P < 0.05 vs. 81-120. 111 In-RP748 and 99m Tc-sestamibi perfusion. The superior resolution of dual isotope ex vivo slice images allowed better localization of myocardial 111 In-RP748 retention within the central infarct area. Figure 6C illustrates the focal uptake of 111 In-RP748 within the nontransmural 99m Tc-sestamibi perfusion defect. Myocardial retention of 111 In-RP748 was apparent in the central infarct region. These images allowed direct correlation of myocardial 111 In-RP748 retention with postmortem TTC staining for necrosis (see Figure 5A) .
Dual-isotope ex vivo imaging of
Canine cell culture studies. In cultured canine endothelial cells, a cy3-labeled analogue of 111 In-RP748 (TA145) localized to αvβ3 at focal cellular contacts in a distribution similar to LM609, an established Ab for αvβ3 integrin (see Figure 7) . This pattern of localization was not seen with an isotype-matched control Ab.
These in vitro data support that our radiolabeled compound does in fact bind to endothelial cells.
Discussion
The 111 In-labeled αvβ3-targeted agent ( 111 In-RP748) may be a valuable targeted marker for noninvasive imaging of angiogenesis following nontransmural myocardial infarction. We employed established chronic rat and canine models of myocardial infarction, which are known to produce nontransmural infarction and peri-infarct ischemia resulting in myocardial angiogenesis. In our rat model of chronic infarction, 111 In-RP748 was selectively retained in the infarcted regions with reduced 201 Tl perfusion. The specificity of 111 In-RP748 retention in myocardial regions with ischemia-induced angiogenesis was supported by the use of
Figure 6
In vivo and ex vivo 111 In-RP748 and 99m Tc-sestamibi ( 99m Tc-MIBI) images from dogs with chronic infarction. Serial in vivo 111 In-RP748 SPECT short axis, vertical long axis (VLA), and horizontal long axis (HLA) images in a dog 3 wks after LAD infarction at 20 min and 75 min after injection in standard format (A). 111 In-RP748 SPECT images were registered with 99m Tc-MIBI perfusion images (third row). The 75-min 111 In-RP748 SPECT images were colored red and fused with 99m Tc-MIBI images (green) to better demonstrate localization of 111 In-RP748 activity within the heart (color fusion, bottom row). Right ventricular (RV) and left ventricular (LV) blood pool activity is seen at 20 min. White arrows indicate region of increased 111 In-RP748 uptake in anterior wall. This corresponds to the anteroapical 99m Tc-sestamibi perfusion defect (yellow arrows). Sequential 99m Tc-sestamibi (top row) and 111 In-RP748 in vivo SPECT HLA images at 90 min after injection (middle row) from a dog at 8 h (acute), 1 wk, and 3 wks after LAD infarction (B). Increased myocardial 111 In-RP748 uptake is seen in the anteroapical wall at all three time points. Color fusion 99m Tc-MIBI (green) and 111 In-RP748 (red) images (bottom row) demonstrate 111 In-RP748 uptake within 99m Tc-MIBI perfusion defect. Ex vivo 99m Tc-sestamibi (left) and 111 In-RP748 (center) images of myocardial slices from a dog 3 wks after LAD occlusion, with color fusion image on the right (C). Short axis slices are in the standard orientation. Yellow arrows indicate anterior location of nontransmural perfusion defect region; white arrows indicate corresponding area of increased 111 In-RP748 uptake. a negative control compound, which demonstrated no increased uptake in the infarct region. These initial rat studies suggested that 111 In-RP748 might be a candidate radiotracer for the noninvasive imaging of myocardial angiogenesis. The use of a canine model permitted the noninvasive serial evaluation of changes in myocardial 111 In-RP748 uptake in relationship to changes of myocardial perfusion. The 111 In-RP748 cleared rapidly from the blood and demonstrated a favorable biodistribution for imaging of myocardial angiogenesis. In vivo SPECT imaging demonstrated focal 111 In-RP748 uptake in the infarct region associated with increased activation of the αvβ3 integrin. Relative 111 In-RP748 activity within the infarct was increased to 370% of nonischemic myocardium at 3 weeks after reperfusion. Analysis of serial in vivo SPECT images suggests that peak uptake of 111 In-RP748 may in fact occur closer to 1 week following reperfusion. Noninvasive imaging strategies similar to that employed in this study may be useful for evaluating angiogenesis and assessing efficacy of angiogenic therapies in patients with chronic ischemia or following myocardial infarction.
Role of αvβ3 integrin in myocardial angiogenesis
Integrins are αβ heterodimeric receptors that mediate divalent cation-dependent cell-cell and cell-matrix adhesion through tightly regulated interactions with ligands (24) . The integrins are involved with many fundamental cellular processes, such as attachment, migration, proliferation, differentiation, and survival. The αvβ3 integrin allows endothelial cells to interact with a wide variety of ECM components. The mAb against αvβ3 (LM609) inhibits angiogenesis by selectively promoting apoptosis of vascular cells (13) . Therefore, the αvβ3 integrin plays a critical role in signaling events vital to survival of vascular cells undergoing angiogenesis. Enhanced expression of the αvβ3 integrin has been previously observed in new blood vessels involved with angiogenesis (14) . Endothelial cell migration is one of the critical steps in angiogenesis that specifically requires αvβ3 integrins (25) .
We observed increased expression of αvβ3 integrin as late as 3 weeks following ischemic injury in endothelial and VSMCs within the central infarct area using immunohistochemical analysis with LM609. Brooks et al. suggested that peak expression of αvβ3 occurs 12-24 hours after initiation of angiogenesis with bFGF (14). Sun et al. recently demonstrated increased expression of β3 in rats following infarction. In these studies of permanent coronary occlusion, β3 mRNA and protein peaked at 7 days after infarction and localized in the endothelial and smooth muscle cells in peri-infarct vessels (26) . Additional experimental studies will be required to define the duration of αvβ3 integrin expression and/or activation following ischemic injury and under conditions of stimulated angiogenesis.
Imaging of αvβ3 integrin
Investigators have previously proposed noninvasive imaging of tumor angiogenesis with compounds specifically targeted at the αvβ3 integrin, using magnetic resonance (MR) imaging (16), positron-emission tomography (PET) (19) , and SPECT imaging (17) . No prior studies have attempted αvβ3 integrintargeted imaging of myocardial angiogenesis.
Targeted SPECT imaging of myocardial angiogenesis offers many advantages over clinical indices or imaging with other modalities. Rather than measuring an effect or consequence of angiogenesis, targeted SPECT imaging directly evaluates the angiogenic process. This is especially important considering the strong placebo effect that has been suggested in clinical trials of angiogenic factors. While clinical studies of angiogenic therapies have demonstrated minor increases in SPECT perfusion, we have demonstrated an approximate two-to fourfold increase in radiotracer uptake in regions of ischemia-induced myocardial angiogenesis. The dual-isotope SPECT perfusion and 111 In-RP748-imaging approach described in this study could easily be adapted for clinical imaging using existing equipment. In this study, we used an 111 In-labeled quinolone targeted at αvβ3 for imaging of ischemia-induced angiogenesis, which permitted serial in vivo SPECT imaging in a canine model of myocardial infarction. Image quality for clinical application could be further improved by use of a 99m Tc-labeled compound targeted at the αvβ3 integrin in combination with 201 Tl perfusion. This radiotracer combination would allow use of higher-resolution low-energy collimators. Absolute quantification of myocardial 111 In-RP748 uptake will ultimately require correction for attenuation, scatter, and partial volume errors. These corrections will become feasible clinically with the availability of hybrid SPECT and x-ray computed tomography imaging systems that will allow for correction of these errors.
Clinical implications
Angiogenesis plays an important role in infarct healing and left ventricular remodeling following myocardial infarction, and infarct remodeling has important implications for the prognosis following myocardial infarction. Therefore, the noninvasive evaluation of angiogenesis may have important implications for prediction of left ventricular remodeling and risk stratification of patients following myocardial infarction. The ability to stimulate myocardial angiogenesis also has applications in the treatment of a host of cardiac disorders involving myocardial ischemia, includ-
Figure 7
Evaluation of αvβ3 integrin localization in cultured canine endothelial cells. LM609, an established mAb of αvβ3 integrin, is localized at cell contact points (left). A cy3-labeled analogue of 111 In-RP748 (TA145) also localized to αvβ3 at focal cellular contact points in a distribution similar to LM609 (middle). No focal cellular uptake was seen with the isotypematched negative control Ab (MOPC21, right). ing chronic coronary artery disease and myocardial infarction. Numerous approaches to exogenously stimulate vessel growth in the myocardium have been explored (2, (5) (6) (7) (8) (9) (10) . While to date a great deal of effort has been focused on the development of strategies to stimulate angiogenesis in the heart, there remains the need for an effective, clinically feasible method for the evaluation of these therapeutic strategies. Most clinical studies have relied on improvement of clinical indicators (i.e., increased treadmill exercise times, reduction in anginal classification), or evaluation of the physiological consequences of angiogenesis, as indirect evidence of myocardial angiogenesis. SPECT, PET, or MR imaging is frequently used to detect changes in myocardial perfusion or function as an indirect physiological indicator of angiogenesis. While these imaging approaches are very useful in identifying regions of moderately to severely diminished perfusion, they may lack the sensitivity to discriminate the potentially small physiological changes that might be expected to result from stimulated angiogenesis in the myocardium. In animal models, immunohistochemical methods and vessel counting are the gold standard for measuring angiogenesis. Immunohistological staining of the endothelium is very effective in identifying blood vessels in a sample of myocardium. These methods involve harvesting of tissue samples and, of course, would be inappropriate for clinical use. Targeted noninvasive SPECT hot spot imaging of the angiogenic process, however, similar to that described here, may be more sensitive for assessing efficacy of angiogenic therapies in patients with chronic ischemia or following myocardial infarction and permit characterization of angiogenesis in humans. Targeted SPECT hot spot imaging of myocardial angiogenesis with 111 In-RP748 may provide increased sensitivity for noninvasive evaluation of angiogenesis over methods that evaluate the physiological consequences of angiogenesis. In experimental studies of angiogenesis, targeted SPECT imaging of the αvβ3 integrin offers the ability to evaluate serially the angiogenic process over time in both small and large animal models. In our experimental models of ischemia-induced angiogenesis, we have also confirmed the increased expression of the αvβ3 integrin with immunohistochemistry. While immunohistochemical techniques permit evaluation of angiogenesis, information on the time course of angiogenic processes can be obtained only by sacrificing many animals at various time points. Although we can not exclude the possibility of additional binding of 111 In-RP748 to inflammatory cells within the infarct region, we have demonstrated clear specific binding of a cy3-labeled homologue of 111 In-RP748 to focal cellular contact points in cultured endothelial cells.
In this study we have demonstrated the ability of 111 In-RP748 SPECT imaging for serial evaluation of injury-induced angiogenesis. Importantly, the imaging approaches developed for these models of chronic infarction may directly translate to evaluation of angiogenesis in patients.
